MECLINERTANT

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C32H31ClN4O5
Molecular Weight	587.065
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=CC(OC)=C1C2=CC(=NN2C3=C4C=CC(Cl)=CC4=NC=C3)C(=O)NC5(C6CC7CC(C6)CC5C7)C(O)=O

InChI

InChIKey=DYLJVOXRWLXDIG-UHFFFAOYSA-N

InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)

HIDE SMILES / InChI

Molecular Formula	C32H31ClN4O5
Molecular Weight	587.065
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8380498
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7754478 | http://adisinsight.springer.com/drugs/800002937

Meclinertant (SR-48692) is the first non-peptide antagonist of neurotensin receptors. It is potent and selective vs the high-affinity binding sites and with a small activity on the levocabastine-sensitive binding sites. It is active on several species including man without partial agonist properties. In vivo, it is active by oral route with a long duration of action and it is able to cross the blood-brain barrier. Meclinertant may be considered a powerful tool for investigating the role of neurotensin in physiological and pathological processes. Meclinertant has been developing for the treatment of anorexia nervosa; colorectal cancer; irritable bowel syndrome; pain; pancreatic cancer; prostate cancer; schizophrenia; small cell lung cancer however its development was discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Neurotensin receptor 1 2 Target ID: CHEMBL4123 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8380498	Antagonist 2849		19.3 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Lung cancer 70 Sources: http://adisinsight.springer.com/drugs/800002937	Primary	Phase III 665	Unknown Approved Use Unknown
Parkinson's disease 232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15190231	Primary	Not Provided 511	Unknown Approved Use Unknown
Schizophrenia 305 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15169685	Primary	Not Provided 511	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
ATP7A 1	supressor 160 Sources: https://pubmed.ncbi.nlm.nih.gov/28790113/	no
ATP7B 1	supressor 160 Sources: https://pubmed.ncbi.nlm.nih.gov/28790113/	no
MRP2 625	supressor 160 Sources: https://pubmed.ncbi.nlm.nih.gov/28790113/	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=124950704	no

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P001EF1	https://www.1pchem.com/search?query=1P001EF1
AK Scientific	X5495	https://aksci.com/item_detail.php?cat=X5495
ApexBio Technology	B7484	https://www.apexbt.com/catalogsearch/result/?q=B7484
Axon MedChem	1164	https://www.axonmedchem.com/product/1164
BOC Sciences	146362-70-1	http://www.bocsci.com/description.asp?cas=146362-70-1
Chem Scene	CS-0025250	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0025250
eMolecules	36366960	https://orderbb.emolecules.com/search/#?query=36366960
eMolecules	46013907	https://orderbb.emolecules.com/search/#?query=46013907
MedChem Express	HY-105189	https://www.medchemexpress.com/search.html?q=HY-105189&ft=&fa=&fp=
Molnova	M11989	https://www.molnova.com/en/serch-list.html?keywords=M11989
MolPort	MolPort-023-276-909	https://www.molport.com/shop/molecule-link/MolPort-023-276-909
MolPort	MolPort-044-727-605	https://www.molport.com/shop/molecule-link/MolPort-044-727-605
MuseChem	R033805	https://www.musechem.com/product/R033805.html
ShangHai Biochempartner	BCP03645	http://www.biochempartner.com/search_BCP03645
Tocris	3721	https://www.tocris.com/search.php?Type=QuickSearch&Value=3721

PubMed

Title	Date	PubMed
Blockade of neurotensin receptors during amphetamine discontinuation indicates individual variability.	2007-04	17276509
Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice.	2004-07	15165840
Neurotensin regulates DARPP-32 thr34 phosphorylation in neostriatal neurons by activation of dopamine D1-type receptors.	2002-04	12064480
Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2.	2001-12	11723247
Mutagenesis and modeling of the neurotensin receptor NTR1. Identification of residues that are critical for binding SR 48692, a nonpeptide neurotensin antagonist.	1998-06-26	9632698
Stable expression of the mouse levocabastine-sensitive neurotensin receptor in HEK 293 cell line: binding properties, photoaffinity labeling, and internalization mechanism.	1998-02-13	9480852
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.	1997-02	9023294
[3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.	1995-05	7746272

Patents

Sample Use Guides

In Vivo Use Guide

Placebo-controlled evaluation of meclinertant (SR-48692) 180 mg/day for the treatment of schizophrenia and schizoaffective disorder. Meclinertant (SR-48692) reverses at low dose (80 micrograms/kg) the turning behavior induced by intrastriatal injection of neurotensin in mice with similar potency whatever the route of administration (i.p. or orally) and with a long duration of action (6 hr).

Route of Administration: Other

In Vitro Use Guide

neurotensin (10⁻¹¹-10⁻⁷ M) significantly stimulated the proliferation of PANC-1 and SR 48692 (10⁻¹¹-10⁻⁷ M) alone had no effect on the growth of PANC-1 cells; however, SR 48692 (10⁻¹⁰-10⁻⁶ M) inhibited the stimulatory effect of neurotensin (10⁻⁹ M).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:59:28 GMT 2025` Edited by `admin` on `Mon Mar 31 17:59:28 GMT 2025`
Record UNII	5JBP4SI96H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MECLINERTANT

Official Name

English

SR-48692

Preferred Name

English

meclinertant [INN]

Common Name

English

REMINERTANT

Common Name

English

2-(((1-(7-CHLORO-4-QUINOLINYL)-5-(2,6-DIMETHOXYPHENYL)-1H-PYRAZOL-3-YL)CARBONYL)AMINO)-TRICYCLO(3.3.1.1(SUP 3,7))DECANE-2-CARBOXYLIC ACID

Systematic Name

English

SR48692

Code

English

Code System Code Type Description

DRUG BANK

DB06455